Sara Workman
Family · Cheyenne, WYNPI 1750930822
Payments from drug & device makers
Across 40 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$111
- Vanda Pharmaceuticals Inc.$88
- Novo Nordisk$67
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$52
- Lilly USA, LLC$49
- Eisai Inc.$43
- plus $314 from 14 others
What the payments were for
- Food & beverage$724100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 7 | $111 |
| Vanda Pharmaceuticals Inc. | 4 | $88 |
| Novo Nordisk | 3 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $52 |
| Lilly USA, LLC | 2 | $49 |
| Eisai Inc. | 3 | $43 |
| Pfizer | 2 | $37 |
| Edwards Lifesciences | 1 | $36 |
| Daiichi Sankyo Inc. | 2 | $35 |
| AbbVie | 2 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Johnson & Johnson | 1 | $23 |
| Vital Connect, Inc | 1 | $21 |
| Phadia US Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Corium, LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| GSK | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
How this compares
$724 in reported general payments places this provider in the 75th percentile of 284 family providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Monohydrate | 12 | $132 |
Paid to pharmacies, not to this prescriber.
Other family in Cheyenne
- Jill GiranyCheyenne$44K
- Kathryn HeimerCheyenne$5K
- Greta SkagenCheyenne$4K
- Jennifer DavisCheyenne$4K
- Anne BarnesCheyenne$4K
- Katherine BrockCheyenne$3K
- Lana SykesCheyenne$3K
- Sheriedan GrannanCheyenne$3K
- Shala SwarmCheyenne$2K
- Heather RobertsCheyenne$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.